NCT05451212 2025-11-10
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Cabaletta Bio
Phase 1 Completed
Cabaletta Bio
Pensionsversicherungsanstalt
AbbVie
Ohio State University
University of Pittsburgh
Endo Pharmaceuticals